Answers are grounded in this paper and cite their sources.
Examines combination therapy effects on migraines and chronic pain, suggesting new treatment options.
The current disclosure address a need in the art by providing methods and compositions for treating migraines and certain pain-related disorders with a combination therapy. Accordingly, aspects of the disclosure relate to a method for treating a migraine, post-traumatic headache, or chronic pain syndrome patient, the method comprising administering to the patient an effective amount of an insulin growth factor receptor (IGFR) activator and a calcitonin gene-related peptide (CGRP) inhibitor. Further aspects relate to a composition comprising insulin-like growth factor-1 (IGF-1) and a CGRP inhibitor. Also provided are methods for treating fibromyalgia or chronic fatigue syndrome in a patient, the method comprising administering to the patient an effective amount of an insulin growth factor receptor (IGFR) activator.
No takes yet. Share an insight, caveat, or question.
KRAIG et al. (2020) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: